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Abstract
Background: This randomized controlled trial aimed to evaluate whether the serum procalcitonin (PCT) level can
be utilized to guide the use of antibiotics in the treatment of acute exacerbations of asthma.
Methods: A total of 293 consecutive patients with suspected asthma attacks from February 2005 to July 2010
participated in this study. 225 patients completed the study. Serum PCT levels, and other inflammatory biomarkers
of all patients were measured. In addition to the standard treatment, the control group received antibiotics
according to the attending physicians’ discretions, while the patients in the PCT group were treated with antibiotics
according to serum PCT concentrations. Antibiotics usage was strongly discouraged when the PCT concentration
was below 0.1 μg/L; discouraged when the PCT concentration was between 0.1 μg/L and 0.25 μg/L; or encouraged
when the PCT concentration was above 0.25 μg/L. The primary endpoint was the determination of antibiotics
usage. The second endpoints included the diagnostic accuracy of PCT and other laboratory biomarkers the
effectiveness of asthma control, secondary ED visits, hospital re-admissions, repeated needs for steroids or dosage
increase, needs for antibiotics, WBC count, PCT levels and FEV1%.
Results: At baseline, two groups were identical regarding clinical, laboratory and symptom score. Probability of the
antibiotics usage in the PCT group (46.1%) was lower than that in the control group (74.8%) (χ2 = 21.97, p < 0.001.
RR = 0.561, 95% CI 0.441-0.713). PCT and IL-6 showed good diagnostic significance for bacterial asthma (r = 0.705,
p = 0.003). The degrees of asthma control in patients were categorized to three levels and were comparable between
the two groups at the six weeks follow-up period (χ2 = 1.62, p = 0.45). There were no significant difference regarding
other secondary outcomes (p > 0.05).
Conclusions: The serum PCT concentration can be used to effectively determine whether the acute asthma patients
have bacterial infections in the respiratory tract, and to guide the use of antibiotics in the treatment of acute asthma
exacerbations, which may substantially reduce unnecessary antibiotic use without compromising the therapeutic
outcomes.
Trial registration: ICTRP ChiCTR-TRC-12002534
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Background
Acute attacks of asthma are episodes that occur sud-
denly and may also occur repeatedly over time. The at-
tacks seriously disturb the patient’s daily and work life,
which impose great burdens on the family and the soci-
ety. There are various causes for acute asthma, including
allergen provocation, drugs, respiratory viruses, bacterial
infections and so on. Since bacterial infection seems to
only play a minor role in acute exacerbations of asthma,
guidelines for asthma management do not recommend
routine use of antibiotics [1]. The majority of patients
with acute asthma are treated with a number of conven-
tional treatment measures, including repetitive administra-
tion of rapid-acting inhaled bronchodilator, introduction
of systemic glucocorticosteroids, oxygen supplementation
and so on, to alleviate the symptoms. However, clinical
signs and symptoms and laboratory parameters of bacter-
ial infection are often inconclusive, which makes it diffi-
cult for physicians to determine accurately in clinical
practice whether there is bacterial infection in the respira-
tory tracts of patients. As a result, most patients are
treated with antibiotics, leading to antibiotics abuse and
bacterial resistance [2].
Procalcitonin (PCT) is the prehormone of calcitonin.
The serum PCT level significantly increases in patients
with bacterial infections but not viral infection or other
inflammatory diseases, granting the PCT test high po-
tential in discriminating bacterial and non-bacterial in-
fections [3-5]. Therefore, the serum PCT level can guide
the use of antibiotics in respiratory tract infections to
prevent the abuse of antibiotics in the intensive care unit
[6-15]. This study aimed to investigate whether the
serum PCT level has diagnostic potential for bacterial
asthma attack, and can serve to guide the use of antibi-
otics in the management of acute exacerbations of
asthma.
Methods
Setting and study population
From February 2005 to July 2010 in the emergency de-
partment of the fifth people’s hospital of Shanghai, 293
suspected acute exacerbation of asthma patients were
screened for eligibility to participate in this study. Of
these, 265 patients meeting the Bronchial Asthma Guide
were eligible and 255 patients completed the study, in-
cluding 123 male patients and 132 female patients. Pa-
tients were eligible for the intervention if they met all
the following criteria: 1) ≥ 18 years old; 2) has any, or all,
of the following clinical features as defined by the Global
Initiative for National Asthma (GINA) Guidelines: dys-
pnea, wheeze, acute cough, increased work of breathing,
increased requirement for beta2-agonist from baseline
use, O2 saturation <95%, a peak expiratory flow (PEF) at
randomization ≤80% of their known best (within the last
12 months) or, in the absence of this information, of
their predicted PEF [1]. The exclusion criteria in the
study are: 1) treatment with antibiotics within two weeks
just before the recruitment; 2) bacterial infection in
other parts of body than the respiratory system; 3) chest
X-ray confirmed pneumonia; 4) suffering from other
chronic respiratory diseases; 5) suffering from severe
organ dysfunction. The protocol was approved by the
Ethics Committee of the Fudan University. Written in-
formed consent was obtained from all patients or their
legally authorized representative.
Experimental protocol
We conducted a randomized, controlled trial. All eligible
patients were assigned to either the PCT-guided antibi-
otics therapy group or the control group, in which the
attending physicians decide the use of antibiotics accord-
ing to usual practice. The flowchart of patients was sum-
marized in Figure 1. Allocation to either intervention
was conducted according to computer-generated ran-
dom numbers produced by an independent statistician.
After randomization, an opaque, sealed and sequentially
numbered envelope containing the PCT or control
protocol was prepared for each subject according to the
group. All patients received similar conventional treat-
ment, such as the repetitive administration of rapid-
acting inhaled bronchodilator, introduction of systemic
glucocorticosteroids and oxygen supplementation. Pro-
calcitonin levels of patients in the PCT group were noti-
fied to the attending physician in charge of this group.
Patients in the PCT group were treated with antibiotics
according to their PCT serum level according the follow-
ing guidelines: antibiotics treatment was strongly dis-
couraged when serum PCT level was less than 0.1 μg/L;
antibiotics treatment was discouraged when serum PCT
level was less than 0.25 μg/L; antibiotics treatment was
encouraged when serum PCT level was greater than
0.25 μg/L [11]. In contrast, attending physicians respon-
sible for patients in the control group remained unaware
of the patients’ procalcitonin concentrations throughout
the study. The control group received antibiotics accord-
ing to the attending physicians’ decision. The patients with
PCT < 0.25 ng/ml in the first PCT test would take the
PCT test again after six to eight hours. The use of antibi-
otics would be determined by the second PCT test result.
We appointed an independent investigator team
blinded to the group assignment to monitor the adher-
ence to the protocol, the safety and efficacy of the inter-
vention, as well as primary and secondary outcomes
during the six-week follow-up period. All patients,
laboratory technicians, investigators and research de-
signers were blinded to patient assignments until the
data analysis was completed. There were no protocol
violations during the study.
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Outcome measures
Our primary endpoint was the use of antibiotics, which
was evaluted by the antibiotic prescription rate and the
relative risk of antibiotic exposure in patients with acute
exacerbations of asthma. The secondary endpoints were
patients’ clinical, laboratory, and lung function outcomes
at the follow-up visit (6 weeks). During the six-week
follow-up period, secondary ED visits, hospital re-
admissions, repeated needs for steroids or dosage increase,
needs for antibiotics, white blood cell count (WBC), PCT
levels and FEV1% were assessed.
Data collection
The serum PCT tests were done using a time-resolved
amplified cryptate emission (TRACE) technology assay
(Kryptor® PCT, Brahms AG, Hennigsdorf, Germany) with
a functional assay sensitivity of 0.06 g/L, about four-
fold above the mean normal PCT level. And several
laboratory parameters of the patients, including the levels
of high sensitivity C-reactive protein (hsCRP), interleukin
6 (IL-6), and tumor necrosis factor α (TNF-α), as well as
WBC, were measured and collected. Arterial blood gas
analysis was also performed on all patients. The usage of
antibiotics in two groups was recorded. Forced expiratory
volume in one second (FEV1) was collected before and
after treatment. The symptom scores of asthma were also
recorded. The patients were categorized into mild,
moderate, and severe subgroups based on the severity
level of their asthma, according to which antibiotics use
was analyzed. The patients were re-categorized during
the six-week follow-up period to assess the asthma
control.
Statistical analysis
We assumed that 75% of the patients in the control group
would use antibiotics and anticipated a 20% decrease in
antibiotics usage in the PCT group. The current sample
size of 128 patients in the PCT group and 127 in the con-
trol group yielded a power of 0.96 to detect difference in
usage of antibiotics at 1-sided 5% significance level. More-
over, the power was 1.00 for non-inferiority testing on
asthma control at a significance level of 2-sided 0.05, “con-
trolled” percentage of 75% in both PCT and control
groups and a non-inferiority limit (d) of 65%.
Discrete variables are expressed as counts (percentages)
and continuous variables as mean ± SD. Comparability of
293 Patients with asthma attacks in emergency 
department assessed for eligibility
22 Did not meet inclusion criteria
2 Death before inclusion
4 No informed consent
265 Randomized
133 Assigned to control group 
127 Completed follow-up at 6 weeks 
assigned to PCT group
1 Died
1 Withdraw from study
2 Lost to follow-up
128 Completed follow-up at 6 weeks 
132 Assigned to PCT group
2 Died
1 Withdraw from study
3 Lost to follow-up
Figure 1 Patient flow chart.
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groups was analyzed by χ2 test, two-sampled t test,
Mann–Whitney U test, as appropriate. Correlation ana-
lyses of the level of serum PCT and levels of hsCRP, IL-6,
TNF-α and WBC were performed using Spearman rank.
A p value less than 0.05 was defined as significant. Data
were analyzed using statistical software (Statistical Pack-
age for Social Sciences, version 14 for Windows; SPSS;
Chicago IL).
Results
The patients were aged between 19 and 78 years old and
the average age was 53 ± 15 years old. Detailed baseline
characteristics of the studied population are presented in
Table 1.
The FEV1 score of both groups was significantly im-
proved after treatment compared with that before treat-
ment. Thirty-two (25.0%) patients in PCT group received
corticosteroids therapy, while 36 (28.3%) patients received
corticosteroids therapy in the control group (χ 2 = 0.13,
p = 0.714). Eight (6.3%) patients in PCT group and nine
(7.1%) patients in the control group (χ 2 = 0.05, p = 0.821)
received mechanical ventilation treatment.
Table 2 showed the details of the levels of inflamma-
tory parameters in patients. The patients with severe-
critical asthma had higher serum PCT levels and IL-6
levels compared with those with mild-moderate asthma
(p < 0.05). Other inflammatory parameters that we tested
showed no significant difference between patients with
mild-moderate asthma and severe-critical asthma. Spear-
man analysis showed that the serum PCT level didn’t
correlate with the level of any laboratory biomarkers ex-
cept for IL-6 (r = 0.705, p = 0.003).
As shown in Table 3, only 46.1% of the patients in
PCT group received antibiotics therapy, which was much
lower compared with 74.8% in the control group (χ2 =
21.97, p = 0.000, RR = 0.561, 95% CI 0.441-0.713). Table 3
also showed that the usage of antibiotics in the PCT
group patients with mild and moderate asthma were sig-
nificantly lower than that in the control group (p <0.01).
There was no significant statistical difference in the
usage of antibiotics between patients with severe and
critical asthma in the two groups.
The asthma control categorized to three levels was
comparable between two groups during the six-week
follow-up period (χ2 =1.62, p = 0.45) (Table 4). There
were no significant difference regarding other secondary
outcomes such as secondary ED visits, hospital re-
admissions, repeated needs for steroids or dosage in-
crease, needs for antibiotics, WBC, PCT levels and
FEV1% between two groups (p > 0.05).
Discussion
This study showed that PCT test could help physicians
to determine whether patients were suffering from re-
spiratory tract bacterial infections. As a result, PCT test
increases the safety level of the treatment strategies of
acute exacerbations of asthma via avoiding antibiotics
abuse. The study published by Briel et al. was not par-
ticularly convincing since only nine asthma patients
were included [9]. Thus far this is the only clinical study
focusing on evaluating the PCT test in its effectiveness
to guide antibiotics usage in treating acute exacerbations
of asthma.
PCT, a protein of 116 amino acids with a molecular
weight of 13 kDa, was discovered 25 years ago as a pro-
hormone of calcitonin produced by C-cells of the thy-
roid gland [16]. Under normal physiological conditions,
PCT is stable in human body [17]. PCT is intracellularly
cleaved by proteolytic enzymes to generate the active
hormone. Circulating levels of PCT in healthy subjects
are below detection limit. It was found in 1993 that the
serum PCT level is elevated in patients with bacterial in-
fection [18]. Since then PCT has become an important
protein in the detection and differential diagnostics of
inflammatory states [3-5]. In microbial infections and in
various forms of inflammation, circulating levels of PCT





Median age, yr 54±14 55±15
Mean Asthma history, yr 25±17 27±18
Gender, no. (%)
Male 64 (50.0) 59 (46.5)
Female 64 (50.0) 68 (53.5)
HR, times/min 95±24 97±26
RR, times/min 24±12 25±10
pH 7.39±0.06 7.38±0.05
SaO2, %* 94±5 95±3
PaO2, mmHg* 79±19 75±17
PaCO2, mmHg* 44±12 42±10
WBC, ×109/L 12.1±4.6 11.9±5.2
hsCRP, mg/L 8.2 (4.5 ~ 15.7) 6.9 (5.1 ~ 17.6)
PCT, ng/ml 0.137 (0.068 ~ 0.252) 0.119 (0.057 ~ 0.267)
IL-6, pg/ml 14.5 (8.3 ~ 26.1) 17.3 (6.7 ~ 31.4)
TNF-α, pg/ml 27.5 (13.4 ~ 49.5) 32.4 (15.7 ~ 52.1)
Severity of asthma
Mild 47 (36.7) 50 (39.4)
Moderate 54 (42.2) 52 (40.9)
Severe 17 (13.3) 17 (13.4)
Critical 10 (7.8) 8 (6.3)
FEV1, % 57.8±17.2 54.3±16.7
Mean symptom score 4.42±0.85 4.35±0.79
Note: Data are presented as No. (%), M (QL ~ QU) or mean ± SD; * = the value
after oxygen.
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increase to several thousand-fold of its normal level
[18,19]. In this case, PCT is produced by other tissues, es-
pecially adherent monocytes and macrophage-activated
adipocytes [19]. This increase correlates significantly with
the severity of the condition and with mortality. However,
PCT level does not increase markedly in patients with
autoimmune inflammation or virus infection [3-5,7]. PCT
is released within four hours in the initial stages of infec-
tion, and peaks in eight hours. Then PCT level begins to
decrease when the infection is under control. The half-life
of PCT is between 20 and 24 hours [17,20]. The serum
PCT level is interfered by hormone levels and can easily
be detected in a short time [21]. Small doses of intraven-
ous lipid polysaccharide in healthy volunteers could in-
duce the production of PCT [21]. The serum PCT can be
detected after two hours and the PCT level increased rap-
idly in the following six to eight hours [21]. The PCT level
reaches the peak l2 to 48 hours later and returns to nor-
mal in two to three days [22]. Respiratory tract infections
induce the acute attacks of asthma. Bacterial infection
seems to just play a minor role in acute exacerbations of
asthma, while virus infection plays a major role [1,23,24].
So many patients with acute asthma don’t need antibi-
otics. Antibiotic therapy benefits those patients with bac-
terial infection by alleviating respiratory tract spasm and
shortening the duration of acute exacerbation, while it
harms patients without bacterial infection by worsening
their condition and increasing the chance of selective bac-
terial resistance [2,23]. The physicians often determine
whether patients suffer from respiratory tract bacterial in-
fections on the basis of sputum characteristics, body
temperature, WBC, CRP and other indicators. However,
clinical signs and symptoms of bacterial infection and
other non-bacterial infections are often indistinguishable,
making it difficult for physicians to determine accurately
in clinical practice whether there is a bacterial infection in
respiratory tract of patients [25]. In general, bacterial cul-
ture is much accurate for diagnosis. However, bacterial
culture takes too long time and it is difficult to obtain ac-
curate information on etiology from asthma patients.
Therefore bacterial culture is not suitable for the emergent
treatment of asthma. And the positive rate of bacterial
culture was limited by the hospital medical standards,
medical technicians operating experience and other fac-
tors, which makes bacterial culture a less effective meas-
ure. When there is no effective approach for physicians to
determine accurately whether there is a bacterial infection,
physicians are more likely to use antibiotic therapy for
most acute asthma patients, leading to antibiotics abuse
and subsequent bacterial resistance [2]. Recent studies
showed that serum PCT level has higher sensitivity in de-
termining whether bacterial infection exist in community
acquired pneumonia, ventilator associated pneumonia and
acute exacerbation of chronic obstructive pulmonary dis-
ease and can guide the usage of antibiotics [6,8,26]. The
serum PCT level is also an early diagnostic index and can
identify sepsis from systemic inflammatory response syn-
drome (SIRS) [3,7,14]. PCT test can objectively determine
the severity of sepsis and be closely related to the severity
of multiple organ dysfunction syndrome (MODS) [3,7,14].
Physicians can judge the direction of progression and
evaluate the therapeutic effectiveness by continuously
monitoring the serum PCT level [27,28].
In this study, we treated the patients with antibiotics
according to PCT serum level. Antibiotics usage was
strongly discouraged when the serum PCT concentration
was below 0.1 μg/L; antibiotics usage was discouraged
when the serum PCT concentration was between 0.1 μg/L
and 0.25 μg/L; and antibiotics usage was encouraged when
the serum PCT concentration was greater than 0.25 μg/L.
The results showed that many patients in the PCT group
did not need antibiotics. The antibiotic usage rate was
lower than that of the control group and the outcome of
treatment was not significantly affected, especially for pa-
tients with mild to moderate asthma. Patients with mild
to moderate asthma in the control group did not need
antibiotics, which implicated that PCT could play an
Table 2 Comparison of inflammatory variables
Level Inflammatory parameters
PCT(ng/ml) hsCRP(mg/L) IL-6(pg/ml) WBC(×109/L) TNF-α(pg/ml)
Mild to Moderate (n = 203) 0.044 (0.027 ~ 0.241) 6.7 (3.8 ~ 13.5) 8.1 (4.5 ~ 13.4) 11.7±4.2 29.3 (12.5 ~ 46.2)
Severe to Critical (n = 52) 0.263 (0.158 ~ 0.482) 7.4 (4.9 ~ 16.4) 21.2 (13.7 ~ 48.1) 12.1±3.8 31.7 (14.1 ~ 50.6)
Statistic value Z = −2.324 Z = −0.538 Z = −3.217 t =0.013 t = −0.615
p value 0.041 0.557 0.036 0.989 0.805
Note: Data are presented as M (QL ~ QU) or mean ± SD.
Table 3 Comparison of the usage of antibiotics
Usage of antibiotics, (%) χ2 p value
PCT group Control group
Mild 16/47 (34.0) 37/50 (74.0) 15.61 <0.01
Moderate 21/54 (38.9) 36/52 (69.2) 9.81 <0.01
Severe 13/17 (76.5) 14/17 (82.4) 0.18 = 0.671
Critical 9/10 (90.0) 8/8 (100.0) 0.85 = 0.357
Total 59/128 (46.1) 95/127 (74.8) 21.97 <0.01
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important role in guiding the use of antibiotics. Although
there was no significant statistical difference in the rate of
antibiotics usage in patients with severe to critical asthma
between the two groups, the trend of antibiotics usage in
PCT group deceased in comparison with the control
group. Accordingly, we believe that PCT is a serum
marker for the appropriate selection of antibiotics in the
treatment of acute attack of asthma. PCT can be quickly
tested to help determine whether there is bacterial infec-
tion and whether antibiotics are needed for the emergency
treatment of patients.
In this study, the serum PCT level and IL-6 level were
correlated, while there is no correlation between the
serum PCT level and levels of other inflammatory indi-
cators, including hsCRP, TNF-α, and WBC. Cellular IL-6
level rises sharply after exposure to bacterial toxins, falls
rapidly as time elapses and has a longer half-life than
TNF-α [29,30]. As a critical mediator of survival follow-
ing pulmonary infection and sepsis, it protects patients
from death by augmenting neutrophil killing of bacteria,
enhancing the release of adrenaline and cortisol, as well
as selectively activating the coagulation system [31,32].
IL-6 has the best discriminative power in sepsis and
non-infectious SIRS, with sensitivity above 80% and spe-
cificity above 70%, which is higher than conventional in-
flammatory markers including CRP and TNF-α [33].
There are limitations in the sensitivity and specificity of
hsCRP, TNF-α, and WBC in judging whether patients
with asthma are also suffering from bacterial infection.
Both PCT and IL-6 levels of patients with severe to crit-
ical asthma in the PCT group were higher than that of
patients with mild to moderate asthma in the same
group. It implicated that patients with severe to critical
asthma may be more prone to bacterial infection than
patients with mild to moderate asthma. Zhang et al.
found that bacterial colonization of the lower airways
was common in patients with chronic severe asthma and
was linked to the duration of asthma and the exacerba-
tions in past years [34,35]. Therefore, PCT test prevents
antibiotics usage mostly in patients with mild to moder-
ate asthma but without bacterial infection, while most
patients with severe to critical asthma do suffer from
bacterial infection and need to be treated with proper
antibiotics.
Conclusion
In summary, this study showed the PCT test can be used
accurately and effectively to determine whether the
acute asthma patients have bacterial infections in re-
spiratory tract, and to guide the use of antibiotics in the
treatment of acute asthma. So PCT test has great value
in reducing unnecessary antibiotics use and in prevent-
ing the occurrences of antibiotics resistance in the treat-
ment of acute asthma, particularly in countries where
patients are suffering from the abuse of antibiotics. Our
study has several limitations. First, we included a rela-
tively small number of patients. However, for the 128 pa-
tients in PCT group and 127 in control group, the power
reached 0.99 with 1-sided 5% significance level to detect
the difference in usage of antibiotics and was 0.88 for
non-inferiority testing with a non-inferiority limit (d) of
65% on asthma control. Second, our results should not
be generalized to other settings such as hospital-
acquired pneumonia and chronic obstructive pulmonary
disease. Third, we did not conduct a formal cost-benefit
study. Larger clinical trials are needed to explore the
overall clinical and economic impact of the reduction of
exposure to antibiotics in asthma patients.
Table 4 Comparison of the levels of asthma control and the follow-up outcomes between two groups
PCT group Control group
Levels of asthma control
Controlled 102 97
Partly controlled 20 19
Uncontrolled 6 11
Total 128 127 χ2 = 1.62 p > 0.05
Other follow-up outcomes
Secondary ED visits 8 13 χ2 = 1.43 p > 0.05
Hospital re-admissions 5 8 χ2 = 0.75 p > 0.05
Repeated needs for steroids or dosage increase* 6 9 χ2 = 0.66 p >0.05
Needs for antibiotics 5 9 χ2 = 1.24 p > 0.05
WBC, ×109/L 8.68±2.47.2 8.32±2.93 t =1.08 p = 0.283
PCT, ng/ml 0.033 (0.024 ~ 0.039) 0.036 (0.027 ~ 0.040) Z = 1.29 p = 0.071
FEV1% 68.20±10.21 70.17±8.89 t = −1.64 p = 0.103
*Means IV, PO or Inhalation; Data are presented as M (QL ~ QU) or mean ± SD.
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